BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: The decrease of miR-153-3p in resistant patients, and subsequent increase in Bcl-2, may attenuate therapy resistance, as CML studies have shown that increased Bcl-2 can decrease apoptosis and mediate therapy resistance [85].